Effects of Sodium–Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction

BACKGROUND: The use of sodium–glucose co-transporter 2 inhibitors (SGLT2i) is currently expanding to cardiovascular risk reduction in non-diabetic subjects, but renal (side-)effects are less well studied in this setting. METHODS: Male non-diabetic Sprague Dawley rats underwent permanent coronary art...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cardiovasc Drugs Ther
Päätekijät: Yurista, Salva R., Silljé, Herman H. W., van Goor, Harry, Hillebrands, Jan-Luuk, Heerspink, Hiddo J. L., de Menezes Montenegro, Luiz, Oberdorf-Maass, Silke U., de Boer, Rudolf A., Westenbrink, B. Daan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer US 2020
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7242237/
https://ncbi.nlm.nih.gov/pubmed/32185580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10557-020-06954-6
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia